Paragon Bioservices has filled a key leadership position with the appointment of seasoned executive Gerard Fleury as chief financial officer.

 

“Our rapid growth, driven by the expanding needs of our client-base over the last few years, has warranted our need to invest in the ranks and capabilities of Paragon’s leadership team,” said President and chief executive officer of Paragon Bioservices, Pete Buzy. “Our focus has been on assembling experts at every level of the organization to expand our capabilities to Phase 3/Commercial to address our clients’ continually advancing needs. As our new CFO, Gerard is an important addition to our leadership team who joins Paragon on the heels of several promotions and new executive hires we announced earlier this year.”   

Mr. Fleury is an accomplished C-level leader with more than 25 years of experience as a CFO, COO or CEO of companies in the biotech, pharmaceutical, healthcare IT, and software industries. Most recently, he was the chief financial officer of Pharmaceutics International, Inc. (Pii), a privately held CDMO providing dosage form development and manufacturing services to the global pharmaceutical industry, where he was responsible for the strategic and financial health of the company.  

Mr. Fleury said, “Paragon is one of the preeminent leaders in the CDMO space for gene therapies and biologics, and it has experienced dramatic growth and success in recent years. I am thrilled to join Pete and the rest of the leadership team to assist them in building a world-class company capable of delivering on client needs throughout the life cycles of their products.”